What Does Managed Care Need to Know about Immunotherapies in the Management of Advanced Renal Cell Carcinoma (RCC)?

A continuing medical education activity sponsored by NAMCP and AAMCN.

Novel Treatment Approaches in the Management of Renal Cell Carcinoma (RCC): A Closer Look at Advances in Immunotherapy in an Evolving Treatment Paradigm is a 3-part live webinar series that will provide attendees with the latest information on Renal Cell Carcinoma

This is Part 3 of the series focusing on What Managed Care Needs to Know about
Immunotherapies in the Management of RCC

This activity is an archive from the webinar held August 9, 2019

This activity is valid from September 1, 2019 to October 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

Managed Care and clinical decision-making in the setting of advanced renal cell carcinoma (RCC) has been undergoing dramatic change in the past few years. The approval of new immunotherapeutic agents has expanded the lines of therapy available to patients, especially around combination options, and raised questions about how rational treatment planning and effective sequencing of new and older standards of care can optimize patient outcomes. Additionally, the benefit of real-world experience and data from subgroup analyses and long-term follow-up of landmark clinical trials continue to refine treatment strategies in advanced RCC.

Upon completion of this activity, participants will be able to:

  • Examine the impact advanced RCC has on pharmacoeconomics and total cost of patient care in oncology

  • Discuss the managed care considerations of current and emerging immunotherapies and combinations by exploring where these agents fit into the current advanced RCC management paradigm

  • Apply methods to enable optimal cost management of immunotherapies to be realized by multiple RCC stakeholders, including managed care organizations

  • Explore interventions to coordinate health plan and affiliated provider's efforts that will lead to better outcomes for patients with advanced RCC


Faculty: Gary Owens, MD
Gary Owens Associates


Gary Owens, MD has no relevant financial relationships to disclose. His presentation has been reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue